Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dulaglutide Clear all
Completed Phase 2 Interventional Results available

A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes

NCT01149421
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
42
States / cities
Phoenix, Arizona • Anaheim, California • Greenbrae, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2015 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 4 Interventional Results available

A Study Comparing the Dulaglutide Pen and the Semaglutide Pen

NCT03724981
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dulaglutide Pen, Semaglutide Pen
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
14
States / cities
Fresno, California • Long Beach, California • Palm Harbor, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 3 Interventional Results available

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

NCT01394952
View directory record Official record
Conditions
Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions
Dulaglutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
9,901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
51
States / cities
Mobile, Alabama • Pell City, Alabama • Phoenix, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY3437943 in Participants With Type 2 Diabetes

NCT04867785
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
LY3437943, Dulaglutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Sheffield, Alabama • Canoga Park, California • Fresno, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

NCT03131687
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
tirzepatide, Dulaglutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Mobile, Alabama • Anaheim, California • Fresno, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 3 Interventional Results available

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

NCT02963766
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dulaglutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Jul 23, 2026, 11:26 AM EDT
Enrolling by invitation No phase listed Observational

An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)

NCT01511393
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2, Medullary Thyroid Carcinoma, Weight Management
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
6,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2039
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)

NCT01191268
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine, LY2189265, Insulin Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
36
States / cities
Concord, California • La Mesa, California • Lancaster, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Jul 23, 2026, 11:26 AM EDT
Completed No phase listed Observational

Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data

NCT07088718
View directory record Official record
Conditions
Type 2 Diabetes, Major Adverse Cardiac Events, Cardiovascular (CV) Risk
Interventions
Tirzepatide, Dulaglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
44,671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of LY2189265 on Two Blood Pressure Drugs

NCT01324388
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Metoprolol, Lisinopril, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
3
States / cities
Honolulu, Hawaii • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Not applicable Interventional Results available

Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

NCT02846233
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
GLP1 receptor agonist, basal insulin, SGLT2 inhibitor, Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Jul 23, 2026, 11:26 AM EDT
Active, not recruiting Phase 4 Interventional

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

NCT07325435
View directory record Official record
Conditions
Type 2 Diabetes (T2DM)
Interventions
SGLT-2 inhibitor, GLP1-RA
Drug
Lead sponsor
MaryAnn Banerji
Other
Eligibility
24 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Type 2 Diabetes Mellitus

NCT01064687
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Exenatide, Placebo, Metformin, Pioglitazone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
78
States / cities
Goodyear, Arizona • Phoenix, Arizona • Cathedral City, California + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 3 Interventional Results available

A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes

NCT02152371
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dulaglutide, Placebo, Insulin Glargine, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
13
States / cities
Fresno, California • San Mateo, California • Tustin, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)

NCT01126580
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Metformin, LY2189265, Placebo (oral), Placebo (subcutaneous)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
807 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
28
States / cities
Huntsville, Alabama • Phoenix, Arizona • Buena Park, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Jul 23, 2026, 11:26 AM EDT
Not yet recruiting Phase 3 Interventional

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

NCT07668336
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Orforglipron, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
17
States / cities
Sacramento, California • San Diego, California • Stamford, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 4 Interventional Results available

GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response

NCT04387201
View directory record Official record
Conditions
Glucose Intolerance, Overweight and Obesity, Drug Effect, Adiposity
Interventions
Cyanocobalamin, Dulaglutide
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 4 Interventional Results available

A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

NCT05564039
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
11
States / cities
Cooper City, Florida • West Palm Beach, Florida • Skokie, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Results available

Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes

NCT00791479
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265 and Lifestyle Measures, Placebo solution and Lifestyle Measures
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
12
States / cities
Concord, California • Lancaster, California • Mission Hills, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

NCT01624259
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
LY2189265, Liraglutide, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Phoenix, Arizona • Chino, California • Fresno, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Jul 23, 2026, 11:26 AM EDT
Completed No phase listed Observational

Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk

NCT07619495
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity, Overweight
Interventions
Semaglutide, Dulaglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
120,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

NCT01621178
View directory record Official record
Conditions
Type 2 Diabetes, Chronic Kidney Disease
Interventions
Dulaglutide, Insulin glargine, Insulin lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
47
States / cities
Montgomery, Alabama • Azusa, California • Granada Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Jul 23, 2026, 11:26 AM EDT
Active, not recruiting No phase listed Observational

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

NCT05220917
View directory record Official record
Conditions
Cardiovascular Events, Type2 Diabetes, Renal Disease
Interventions
SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
781,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 23, 2026, 11:26 AM EDT